Loading...

Organon & Co.

OGNNYSE
Healthcare
Drug Manufacturers - General
$10.21
$0.14(1.39%)

Organon & Co. (OGN) Stock Overview

Explore Organon & Co.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 73.8/100

Key Financials

Market Cap2.7B
P/E Ratio3.49
EPS (TTM)$2.88
ROE1.82%
Fundamental Analysis

AI Price Forecasts

1 Week$9.68
1 Month$9.94
3 Months$10.68
1 Year Target$13.24

OGN Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Organon & Co. (OGN) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 58.48, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $13.24.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 3.49 and a market capitalization of 2.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Frequently Asked Questions

;